Cholangiocarcinoma Clinical Trials

84 recruiting

Cholangiocarcinoma Trials at a Glance

173 actively recruiting trials for cholangiocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 73 trials, with the heaviest enrollment activity in Houston, Hangzhou, and Shanghai. Lead sponsors running cholangiocarcinoma studies include M.D. Anderson Cancer Center, Fudan University, and National Cancer Institute (NCI).

Browse cholangiocarcinoma trials by phase

Treatments under study

About Cholangiocarcinoma Clinical Trials

Looking for clinical trials for Cholangiocarcinoma? There are currently 84 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cholangiocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cholangiocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 173 trials

Recruiting
Phase 1Phase 2

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

Pancreatic CancerCholangiocarcinomaPancreatic Cyst+4 more
University of Nottingham160 enrolled1 locationNCT07206355
Recruiting
Phase 2

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

CholangiocarcinomaBile Duct CancerHilar Cholangiocarcinoma
Jinbo Yue38 enrolled1 locationNCT07030140
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2

FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers

CholangiocarcinomaPancreatic Adenocarcinoma
University Hospital, Bordeaux120 enrolled1 locationNCT07478523
Recruiting
Phase 1

A Study of MGC028 in Participants With Advanced Solid Tumors

CholangiocarcinomaColorectal CarcinomaPancreatic Carcinoma+2 more
MacroGenics124 enrolled7 locationsNCT06723236
Recruiting
Phase 2

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Intrahepatic Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center164 enrolled11 locationsNCT04891289
Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

CholangiocarcinomaPancreas CancerColorectal Neoplasms+2 more
National Cancer Institute (NCI)1,800 enrolled1 locationNCT01915225
Recruiting
Phase 1

A Study of PHST001 in Advanced Solid Tumors

Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

CholangiocarcinomaBile Duct CancerCholangiocarcinoma Non-resectable+2 more
Beth Israel Deaconess Medical Center30 enrolled1 locationNCT05655949
Recruiting
Phase 1Phase 2

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled28 locationsNCT07213791
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting

Molecular Epidemiology of Biliary Tree Cancers

CholangiocarcinomaMalignant Digestive System Neoplasm
M.D. Anderson Cancer Center1,500 enrolled1 locationNCT05179486
Recruiting
Phase 2

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma
M.D. Anderson Cancer Center24 enrolled1 locationNCT05967182
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting
Not Applicable

Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy

Intrahepatic CholangiocarcinomaLocally Advanced Intrahepatic Cholangiocarcinoma
Assistance Publique - Hôpitaux de Paris36 enrolled1 locationNCT06910722
Recruiting

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

CholangiocarcinomaHepatocellular CarcinomaHepatic Carcinoma+4 more
City of Hope Medical Center400 enrolled5 locationsNCT06342414